<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984152</url>
  </required_header>
  <id_info>
    <org_study_id>08102303-IRB01</org_study_id>
    <secondary_id>Merck IISP #33421</secondary_id>
    <nct_id>NCT00984152</nct_id>
  </id_info>
  <brief_title>Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women</brief_title>
  <acronym>ICE-002</acronym>
  <official_title>Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, &amp; Immune Parameters in Different Compartments, Including Gut &amp; Genital Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Raltegravir not only has a unique mechanism of action, but may also have other unique effects&#xD;
      on suppression of viral replication, viral reservoir, and immune reconstitution in blood and&#xD;
      other important compartments. This may in part be due to the pharmacokinetics of Raltegravir&#xD;
      in blood and gut tissue. Efavirenz will be the comparator antiretroviral drug in this study,&#xD;
      with both drugs being used as part of a three-drug regimen with tenofovir and emtricitabine.&#xD;
&#xD;
      The primary objectives are to determine differences in the effects of 2 anti-retroviral&#xD;
      regimens, Raltegravir + Truvada versus Atripla, with respect to:&#xD;
&#xD;
        1. Viral load in plasma, genital tract (vaginal secretions), and gut (by in situ&#xD;
           hybridization).&#xD;
&#xD;
        2. Latent viral reservoir (pro-viral DNA) in the peripheral blood and genital tract.&#xD;
&#xD;
        3. Immune effects (CD4/CD8 immunophenotypes) in gut and PBMCs and plasma cytokine profiles.&#xD;
&#xD;
      The secondary objective is to determine the pharmacokinetics of Raltegravir in blood and gut&#xD;
      tissue; relative tissue/compartment penetration compared to Efavirenz.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, prospective, randomized (1:1), multicenter, open label study comparing&#xD;
      the effects of two HAART regimens:&#xD;
&#xD;
        -  Arm A: Raltegravir 400 mg PO BID + TDF/FTC (Truvada, 300/200 mg) One PO Daily&#xD;
&#xD;
        -  Arm B: Efavirenz + TDF/FTC (Atripla) Once PO Daily&#xD;
&#xD;
      The following local sites: Mt. Sinai, Rush University Medical Center, Stroger Hospital,&#xD;
      University of Chicago and University of Illinois will work together to enroll 10 eligible&#xD;
      women meeting all eligibility criteria (5 per study arm) over a one year time period. These&#xD;
      10 women will be randomized 1:1 to receive either TDF/FTC + Raltegravir or TDF/FTC +&#xD;
      Efavirenz (Atripla). There will be 2 baseline evaluations prior to initiation of study&#xD;
      therapy. Subjects will be followed for 48 weeks after initiation of study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Decision not to go forth with study.&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load in plasma, genital tract (vaginal secretions), and gut (by in situ hybridization)</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Latent viral reservoir (pro-viral DNA) in the peripheral blood and genital tract</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune effects (CD4/CD8 immunophenotypes) in gut and PBMCs and plasma cytokine profiles</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetics of Raltegravir in blood and gut tissue; relative tissue/compartment penetration compared to Efavirenz</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF/FTC + Efavirenz (Atripla) Once-Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily</intervention_name>
    <description>TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TDF/FTC Once-Daily + Raltegravir (Isentress) 400 mg Orally Twice-Daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/FTC + Efavirenz (Atripla) Once-Daily</intervention_name>
    <description>TDF/FTC + Efavirenz (Atripla) Once-Daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible subjects will be antiretroviral naïve (&lt; 7 days of HAART at any time prior to&#xD;
             entry) with plasma HIV-1 RNA &gt; 50,000 copies/mL (obtained within 90 days prior to&#xD;
             study entry by any laboratory that has a CLIA certification or its equivalent) and&#xD;
             moderate immune suppression within 90 days prior to study entry.&#xD;
&#xD;
          2. HIV-1 infected, as documented by any licensed ELISA test kit and confirmed by Western&#xD;
             blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA,&#xD;
             or a second antibody test by a method other than ELISA is acceptable as an alternative&#xD;
             confirmatory test. Alternatively, if a licensed ELISA is not available, two HIV-1 RNA&#xD;
             values &gt;2000 copies/mL at least 24 hours apart performed by any laboratory that has&#xD;
             CLIA certification or its equivalent may be used to document infection.&#xD;
&#xD;
          3. Female sex, Age &gt; 18 and &lt; 60 years, Pre-menopausal.&#xD;
&#xD;
          4. Screening CD4+ T-cell count between 200-350 cells/mm3 obtained within 90 days prior to&#xD;
             study entry by any laboratory that has a CLIA certification or its equivalent.&#xD;
&#xD;
          5. The absence of exclusionary resistance mutations on a genotypic resistance assay&#xD;
             (absence of exclusionary NRTI or NNRTI resistance mutations by genotype testing)&#xD;
&#xD;
          6. Antiretroviral (ARV) drug-naïve (defined as 7 days of ARV treatment at any time prior&#xD;
             to entry).&#xD;
&#xD;
          7. Laboratory values obtained within 45 days prior to study entry:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) 500/mm3&#xD;
&#xD;
               -  Hemoglobin 8.0 g/dL&#xD;
&#xD;
               -  Platelet count 40,000/mm3&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase 5 ULN&#xD;
&#xD;
               -  Total bilirubin 2.5 x ULN&#xD;
&#xD;
               -  Calculated creatinine clearance ≥60 mL/min as estimated by the Cockcroft-Gault&#xD;
                  equation:&#xD;
&#xD;
                    -  For women, multiply the result by 0.85 = CrCl (mL/min)&#xD;
&#xD;
          8. Negative serum or urine pregnancy test within 48 hours prior to initiating study&#xD;
             medications unless otherwise specified by product labeling.&#xD;
&#xD;
               -  Female candidates of reproductive potential is defined as women who have had&#xD;
                  regular menses over the preceding 24 months&#xD;
&#xD;
          9. Contraception requirements for women who have not undergone surgical sterilization&#xD;
             (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation).&#xD;
&#xD;
         10. Female candidates of reproductive potential, who are participating in sexual activity&#xD;
             that could lead to pregnancy, must agree to the following:&#xD;
&#xD;
               -  If the regimen does not include EFV, they must agree to use at least one reliable&#xD;
                  method of contraception while receiving the protocol-specified drugs and for 6&#xD;
                  weeks after stopping the medications.&#xD;
&#xD;
               -  If the regimen includes EFV, they must agree to use two reliable methods of&#xD;
                  contraception: a barrier method of contraception (e.g., condoms, diaphragm, or&#xD;
                  cervical cap with or without spermicide) together with another reliable form of&#xD;
                  contraceptive (e.g., a second barrier method, an IUD, or a hormone-based&#xD;
                  contraceptive) while receiving EFV and for 6 weeks after stopping EFV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Menopausal (may affect quantity of genital tract secretions) or any serious illness&#xD;
             that requires treatment and/or hospitalization until the patient completes therapy&#xD;
&#xD;
          2. Any active infection, including co-infection with hepatitis B or C&#xD;
&#xD;
          3. Any neoplasm&#xD;
&#xD;
          4. Immunosuppressive therapy&#xD;
&#xD;
          5. Requirement for any medications that are prohibited by any of the study treatments&#xD;
&#xD;
          6. Significant liver or renal dysfunction&#xD;
&#xD;
          7. Baseline resistance to any of the study drugs by genotypic testing&#xD;
&#xD;
               -  NRTI: M41L, K65 R, D76N, T69D, K70R, L74V/I, y115F, Q151M, M184V, L210W, T215any,&#xD;
                  K219Q/E&#xD;
&#xD;
               -  NNRTI:L100I, K103N, V106A/M, V108I, Y181C/I, Y188C/L/H, G190anyA/S&#xD;
&#xD;
          8. Alcohol or substance abuse problems or psychiatric conditions that impair the ability&#xD;
             of the subject to comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan L. Landay, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ruth M. Rothstein CORE Center (of Cook County)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Alan L. Landay, Ph.D.</name_title>
    <organization>Rush University Medical Center</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Women</keyword>
  <keyword>Viral Suppression</keyword>
  <keyword>Viral Reservoir</keyword>
  <keyword>Immune Parameters</keyword>
  <keyword>Gut</keyword>
  <keyword>Genital Tract</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

